Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Phase II Switching Clear all
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)

NCT03180619
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Los Angeles, California • San Jose, California • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2021 · Synced Sep 3, 2026, 9:30 PM EDT
Terminated Not applicable Interventional Results available

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

NCT00726830
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Spartanburg, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Sep 3, 2026, 9:30 PM EDT
Completed Phase 2 Interventional

A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible

NCT00000939
View directory record Official record
Conditions
HIV Infections
Interventions
Hydroxyurea, Efavirenz, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
19
States / cities
Menlo Park, California • San Jose, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 3, 2026, 9:30 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

NCT00039741
View directory record Official record
Conditions
HIV Infections
Interventions
NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT), NNRTIs (EFV, NVP), PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
30 Days to 18 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
29
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 3, 2026, 9:30 PM EDT
Recruiting No phase listed Observational

Behavioral AI to Predict and Increase Peritoneal Dialysis Uptake

NCT06533254
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Predicting choice of dialysis, Behavioral nudges
Other · Behavioral
Lead sponsor
Scaled Insights
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2024 · Synced Sep 3, 2026, 9:30 PM EDT
Active, not recruiting Phase 2 Interventional Results available

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

NCT04539808
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8, Stage III Pancreatic Cancer American Joint Committee on Cancer v8, Stage IV Pancreatic Cancer American Joint Committee on Cancer v8
Interventions
Capecitabine, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Losartan Potassium, Oxaliplatin, Radiation Therapy, Resection, Diagnostic Imaging, Biospecimen Collection, Gemcitabine, Nab paclitaxel
Drug · Radiation · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 3, 2026, 9:30 PM EDT
Completed Phase 4 Interventional Results available

PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment

NCT04634162
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Cangrelor, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Sep 3, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury

NCT00580970
View directory record Official record
Conditions
Prostate Cancer
Interventions
lovastatin
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Male only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
3
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 3, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa

NCT03799627
View directory record Official record
Conditions
Anemia, Dialysis-dependent Chronic Kidney Disease
Interventions
Vadadustat, Epoetin Alfa, Vadadustat TIW
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 99 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
41
States / cities
Fresno, California • Granada Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Sep 3, 2026, 9:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

NCT00804934
View directory record Official record
Conditions
Wet AMD
Interventions
Lucentis
Drug
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Sep 3, 2026, 9:30 PM EDT
Recruiting Not applicable Interventional

Improving ADHD Teen Driving - Virtual Reality

NCT06960980
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
FOCAL+, VR-FOCAL+
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
16 Years to 19 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 3, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis

NCT01104025
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis
Interventions
ATG, rabbit, Etoposide, Methotrexate, hydrocortisone, Dexamethasone
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 3, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation

NCT01744665
View directory record Official record
Conditions
CML
Interventions
nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
54
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Sep 3, 2026, 9:30 PM EDT
Completed Phase 2 Interventional

Changing to Nonprotease Inhibitor Treatment to Improve Side Effects

NCT00021463
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Abacavir sulfate, Lamivudine and Zidovudine, Abacavir sulfate, Efavirenz, Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2011 · Synced Sep 3, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is

NCT03635099
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo (fasted), BI 25 mg (fasted), BI 50 mg (fasted), BI 100 mg (fasted), BI 200 mg (fasted), Placebo (fed), BI 400 mg once daily (fed), BI 200 mg twice daily, 400 mg total (fed)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 3, 2026, 9:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Gender Differences in Switching From Smoking Regular Cigarettes to E-Cigarettes

NCT03856515
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Nicotine Replacement, Questionnaire Administration, Electronic Cigarette
Drug · Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years and older
Enrollment
169 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 3, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer

NCT02954536
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
pembrolizumab, trastuzumab, capecitabine, cisplatin, Oxaliplatin, 5-Fluorouracil
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Sep 3, 2026, 9:30 PM EDT
Recruiting Phase 2 Interventional

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

NCT04363164
View directory record Official record
Conditions
Castration Resistant Metastatic Prostate Cancer
Interventions
Testosterone cypionate, Enzalutamide, Testosterone enanthate
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
6
States / cities
San Diego, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 3, 2026, 9:30 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis

NCT04616963
View directory record Official record
Conditions
Hiv, Hormone Therapy
Interventions
Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg, Emtricitabine Tenofovir Alafenamide 200/25 mg
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 3, 2026, 9:30 PM EDT
Completed Not applicable Interventional Results available

Optimize Low Back Pain

NCT03859713
View directory record Official record
Conditions
Low Back Pain, Chronic Pain
Interventions
Physical Therapy, Cognitive Behavioral Therapy, Mindfulness, Phase I Treatment, Phase II Switching
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 64 Years
Enrollment
749 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Baltimore, Maryland • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 3, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis

NCT01116427
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
abatacept, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
20
States / cities
Phonix, Arizona • Berkeley, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Sep 3, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT01718353
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
DOCETAXEL (XRP6976), CABAZITAXEL (XRP6258), Prednisone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Indianapolis, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Sep 3, 2026, 9:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant

NCT04418466
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone
Combination Product
Lead sponsor
Delpor, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Long Beach, California • Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 3, 2026, 9:30 PM EDT